RxDoctor Payments DataLook up a doctor →

Kathryn McMullan, MD

Allergy & Immunology · Hattiesburg, MSNPI 1518164490

Payments from drug & device makers

$10,118in general payments, 2019–2025

Across 454 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • Regeneron Healthcare Solutions, Inc.$2K
  • AstraZeneca$1K
  • CSL Behring$610
  • Genentech USA, Inc.$423
  • Novartis$402
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$1,30013%
  • Speaking & faculty fees$250%
  • Food & beverage$8,74386%
  • Education$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,118 in reported general payments places this provider in the 45th percentile of 28 allergy & immunology providers in Mississippi.

See all allergy & immunology providers in Mississippi

Medicare billing

Part B allowed, 2024
$729,971
Medicare patients
236
Services billed
28,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrladeyoBerotralstat Hydrochloride14$614,988
Trelegy ElliptaFluticasone/Umeclidin/Vilanter190$179,314
Dupixent SyringeDupilumab32$131,750
Spiriva RespimatTiotropium Bromide43$28,851
SymbicortBudesonide/Formoterol Fumarate64$22,785
Advair HfaFluticasone Propion/Salmeterol49$19,363
Breo ElliptaFluticasone/Vilanterol22$17,253
Azelastine Hcl392$13,361
Arnuity ElliptaFluticasone Furoate27$8,857
Epinephrine40$8,500
Ipratropium Bromide165$6,888
Fluticasone Propionate350$5,703
Albuterol Sulfate HfaAlbuterol Sulfate167$4,913
Incruse ElliptaUmeclidinium Bromide11$3,959
BreynaBudesonide/Formoterol Fumarate23$3,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Biocryst US Sales Co., LLCOrladeyo$28$614,98814 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$3,802$209,384250 claims
Boehringer IngelheimSpiriva Respimat$81$28,85143 claims
AstraZenecaSymbicort$1,365$22,78564 claims
Hikma Pharmaceuticals USAEpinephrine$15$8,50040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 28 allergy & immunology providers in Mississippi.

Other allergy & immunology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →